Assessment of Immune Status in Patients with Mismatch Repair Deficiency Endometrial Cancer

References

• Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2018;110(4):354–361. doi:10.1093/jnci/djx214
   PubMedGoogle Scholar
• T A, Mk M, L S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2). doi:10.1038/bjc.2015.190
   Web of Science ®Google Scholar
• Kandoth C, Schultz N, Cherniack AD, et al.; Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. doi:10.1038/nature12113
   PubMed Web of Science ®Google Scholar
• Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388(23):2159–2170. doi:10.1056/NEJMoa2302312
   PubMed Web of Science ®Google Scholar
• Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388(23):2145–2158. doi:10.1056/NEJMoa2216334
   PubMed Web of Science ®Google Scholar
• Willvonseder B, Stögbauer F, Steiger K, et al. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations. Cancer Immunol Immunother. 2021;70(6):1679–1689. doi:10.1007/s00262-020-02813-3
   PubMed Web of Science ®Google Scholar
• Gupta D, Heinen CD. The mismatch repair-dependent DNA damage response: mechanisms and implications. DNA Repair. 2019;78:60–69. doi:10.1016/j.dnarep.2019.03.009
   PubMed Web of Science ®Google Scholar
• He Y, Zhang L, Zhou R, Wang Y, Chen H. The role of DNA mismatch repair in immunotherapy of human cancer. Int J Biol Sci. 2022;18(7):2821–2832. doi:10.7150/ijbs.71714
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The Immune Landscape of Cancer. Immunity. 2018;48(4):812–830.e14. doi:10.1016/j.immuni.2018.03.023
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:10.1126/science.aan6733
   PubMed Web of Science ®Google Scholar
• Chika N, Eguchi H, Kumamoto K, et al. Prevalence of Lynch syndrome and Lynch-like syndrome among patients with colorectal cancer in a Japanese hospital-based population. Jpn J Clin Oncol. 2017;47(2):191. doi:10.1093/jjco/hyw200
   PubMed Web of Science ®Google Scholar
• Hampel H, Pearlman R, de la Chapelle A, et al. Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. Gynecol Oncol. 2021;160(1):161–168. doi:10.1016/j.ygyno.2020.10.012
   PubMed Web of Science ®Google Scholar
• Xia Y, Li W, Li Y, et al. The clinical value of the changes of peripheral lymphocyte subsets absolute counts in patients with non-small cell lung cancer. Transl Oncol. 2020;13(12):100849. doi:10.1016/j.tranon.2020.100849
   PubMed Web of Science ®Google Scholar
• Khushman MM, Toboni MD, Xiu J, et al. Differential responses to immune checkpoint inhibitors are governed by diverse mismatch repair gene alterations. Clin Cancer Res off J Am Assoc Cancer Res. 2024. doi:10.1158/1078-0432.CCR-23-3004
   Google Scholar
• Kim MK, So KA, Chun YK, et al. Clinicopathologic significance of mismatch repair protein expression in endometrioid endometrial cancer. Taiwan J Obstet Gynecol. 2023;62(5):724–728. doi:10.1016/j.tjog.2023.07.015
   PubMed Web of Science ®Google Scholar
• Doulgeraki T, Vagios S, Kavoura E, et al. Mismatch repair status in high-grade endometrial carcinomas of endometrioid and non-endometrioid type. J BUON off J Balk Union Oncol. 2019;24(5):2020–2027.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. doi:10.1016/S1470-2045(17)30904-X
   PubMed Web of Science ®Google Scholar
• Bohaumilitzky L, von Knebel Doeberitz M, Kloor M, Ahadova A. Implications of hereditary origin on the immune phenotype of mismatch repair-deficient cancers: systematic literature review. J Clin Med. 2020;9(6):1741. doi:10.3390/jcm9061741
   PubMed Web of Science ®Google Scholar
• Ramchander NC, Ryan NAJ, Walker TDJ, et al. Distinct immunological landscapes characterize inherited and sporadic mismatch repair deficient endometrial cancer. Front Immunol. 2020;10:3023. doi:10.3389/fimmu.2019.03023
   PubMed Web of Science ®Google Scholar
• Evans CFM, Galustian C, Bodman-Smith M, Dalgleish AG, Kumar D. The effect of colorectal cancer upon host peripheral immune cell function. Colorectal Dis. 2010;12(6):561–569. doi:10.1111/j.1463-1318.2009.01819.x
   PubMed Web of Science ®Google Scholar
• Maby P, Tougeron D, Hamieh M, et al. Correlation between Density of CD8+ T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res. 2015;75(17):3446–3455. doi:10.1158/0008-5472.CAN-14-3051
   PubMed Web of Science ®Google Scholar
• Salem ME, Bodor JN, Puccini A, et al. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. Int, J, Cancer. 2020;147(10):2948–2956. doi:10.1002/ijc.33115
   PubMed Web of Science ®Google Scholar
• Lee M, Samstein RM, Valero C, Chan TA, Morris LGT. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. Hum Vaccines Immunother. 2019;16(1):112–115. doi:10.1080/21645515.2019.1631136
   PubMed Web of Science ®Google Scholar